⌕
Silence Therapeutics · SLN · Nasdaq
Tenet — · insufficient data
Compare
$19.80−0.15%At close
$19.80−0.03 (−0.15%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Silence Therapeutics (SLN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is SLN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Business WireNov 12, 2026 · 08:00 ET
Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results fo…

SLN −0.2% todayRead at source ↗
● Business WireNov 4, 2026 · 09:00 ET
Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that data …

SLN −0.2% todayRead at source ↗
● Business WireOct 21, 2026 · 15:35 ET
Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Silence Therapeutics…

SLN −0.2% todayRead at source ↗
● GuruFocusOct 20, 2026 · 13:00 ET
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?

Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 20, 2026Insiders may stand to receive substantial financial benef…

SLN −0.2% todayRead at source ↗
● Zacks Investment ResearchOct 20, 2026 · 10:56 ET
Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?

The consensus price target hints at an 82.8% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisio…

SLN −0.2% todayRead at source ↗
● GlobeNewsWireOct 20, 2026 · 08:03 ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG)

BALA CYNWYD, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith…

SLN −0.2% todayRead at source ↗
● Proactive InvestorsOct 19, 2026 · 11:50 ET
Silence Therapeutics jumps 59% on Merck takeover

Silence Therapeutics PLC (NASDAQ:SLN, FRA:XRP1, OTC:SLNCF), the clinical-stage biotechnology company, surged 59% to $6.11 after agreeing to a $1.3 billion takeover by Merck KGaA, the German pharmaceutical and technology …

SLN −0.2% todayRead at source ↗
● BenzingaOct 19, 2026 · 10:05 ET
Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.…

SLN −0.2% todayRead at source ↗
● Business WireOct 19, 2026 · 09:40 ET
SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Silence Therapeutics plc (NASDAQ: SLN) to Merck for $20.00 in cash per American Depositary Share.Halper Sadeh encoura…

SLN −0.2% todayRead at source ↗
● WSJOct 19, 2026 · 08:48 ET
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion

Merck said it is offering $20 in cash for each American depositary share for Nasdaq-listed Silence Therapeutics, more than double the target's closing price as of Friday.…

SLN −0.2% todayRead at source ↗
● Business WireOct 19, 2026 · 08:00 ET
Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive agreement to acquire Silence Therapeutics plc (Nasdaq: SLN), a gl…

SLN −0.2% todayRead at source ↗
● Business WireOct 19, 2026 · 08:00 ET
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN) (“Silence”), a biotechnology company developing precision engineered medicines using its proprietary siRNA technology, today announ…

SLN −0.2% todayRead at source ↗
● Zacks Investment ResearchOct 14, 2026 · 10:36 ET
Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Silence Therapeutics (SLN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revisin…

SLN −0.2% todayRead at source ↗
● Zacks Investment ResearchOct 13, 2026 · 13:01 ET
Silence Therapeutics (SLN) Upgraded to Buy: Here's Why

Silence Therapeutics (SLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).…

SLN −0.2% todayRead at source ↗
● Defense WorldSep 21, 2026 · 06:15 ET
Absci (NASDAQ:ABSI) vs. Silence Therapeutics (NASDAQ:SLN) Head to Head Contrast

Silence Therapeutics (NASDAQ: SLN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the stre…

SLN −0.2% todayRead at source ↗
● Seeking AlphaSep 16, 2026 · 13:31 ET
Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

SLN −0.2% todayRead at source ↗

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.